Hana Jansová

发表

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites

D. Richardson, K. Vávrová, D. Kalinowski, 2015, PloS one.

Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials

D. Richardson, D. Kalinowski, J. Roh, 2019, Analytical and Bioanalytical Chemistry.

Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.

J. Bureš, M. Machácek, Hana Jansová, 2016, Toxicology.

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

Qin Wang, Eliška Potůčková, M. Machácek, 2014, Free radical biology & medicine.

Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.

Qin Wang, J. Bureš, J. Roh, 2016, Toxicology.

2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress.

J. Kubeš, J. Roh, Hana Jansová, 2018, Chemical research in toxicology.

Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties

D. Richardson, K. Vávrová, D. Kalinowski, 2014, PloS one.

Cardioprotective Potential of Iron Chelators and Prochelators.

Hana Jansová, T. Šimůnek, H. Jansová, 2019, Current medicinal chemistry.

Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine

K. Vávrová, Lenka Applová, J. Roh, 2022, Scientific Reports.

Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells

M. Štěrba, M. Machácek, Hana Jansová, 2013, PloS one.

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity

N. Váňová, J. Chládek, M. Štěrba, 2021, Scientific Reports.

LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH).

J. Klimeš, Qin Wang, P. Mladěnka, 2015, Journal of pharmaceutical and biomedical analysis.

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents

D. Richardson, D. Kalinowski, J. Chládek, 2015, Oncotarget.

Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs

D. Richardson, D. Kalinowski, Eliška Potůčková, 2014, PloS one.

Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.

K. Vávrová, Hana Jansová, P. Hašková, 2012, Chemico-biological interactions.

Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo

D. Richardson, M. Muller, K. Vávrová, 2015 .

Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.

J. Chládek, M. Štěrba, M. Adamcová, 2016, Journal of molecular and cellular cardiology.

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.

M. Štěrba, J. Kubeš, M. Adamcová, 2019, Clinical science.

Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?

M. Štěrba, J. Bureš, M. Adamcová, 2016, Toxicology.

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

Qin Wang, Eliška Potůčková, Hana Jansová, 2014, Free radical biology & medicine.